A COMPREHENSIVE REVIEW OF CLINICAL TRIALS ON EGFR INHIBITORS SUCH AS CETUXIMAB AND PANITUMUMAB AS MONOTHERAPY AND IN COMBINATION FOR TREATMENT OF METASTATIC COLORECTAL CANCER

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

YAZDI MOHAMMAD HOSSEIN; FARAMARZI MOHAMMAD ALI; NIKFAR SHEKOUFEH; ABDOLLAHI MOHAMMAD

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Avicenna Journal of Medical Biotechnology Year:2015 | Volume:7 | Issue:4 (27) Page(s): 134-144

Download Full-Text

View:

482

Download:

226

Cites:

Information Journal Paper

Title

A COMPREHENSIVE REVIEW OF CLINICAL TRIALS ON EGFR INHIBITORS SUCH AS CETUXIMAB AND PANITUMUMAB AS MONOTHERAPY AND IN COMBINATION FOR TREATMENT OF METASTATIC COLORECTAL CANCER

Author(s)

YAZDI MOHAMMAD HOSSEIN | FARAMARZI MOHAMMAD ALI | NIKFAR SHEKOUFEH | ABDOLLAHI MOHAMMAD | Issue Writer Certificate

Keywords

ANTI-EGFR DRUGS

CETUXIMAB

METASTATIC COLORECTAL CANCER

PANITUMUMAB

Abstract

Metastatic colorectal cancer is the fourth most common cause of death due to cancer after those of lung, stomach, and liver. Anti epidermal growth factor receptor drugs as a targeting therapy seem to be good candidates for curing METASTATIC COLORECTAL CANCER. Two available anti epidermal growth factor receptor monoclonal antibodies are CETUXIMAB and PANITUMUMAB which have been approved for METASTATIC COLORECTAL CANCER treatment. Through the available literature on NCBI and clinical trials, 31 clinical trials in which CETUXIMAB or PANITUMUMAB as monotherapy or in combination with chemotherapy were used for the treatment of METASTATIC COLORECTAL CANCER patients in different line settings and 12 clinical trials in which bevacizumab was used for being compared with anti epidermal growth factor receptor monoclonal antibodies or chemotherapy were chosen for reviewing and comparing the results of overall survival, progression free survival and adverse effects. CETUXIMAB and PANITUMUMAB are well accepted for the treatment of mCRC patients at all stages in different line settings. Although CETUXIMAB administration in METASTATIC COLORECTAL CANCER patients is mostly associated with better overall survival and PANITUMUMAB results in better progression free survival, to confirm the superiority of each of them in the treatment protocol of epidermal growth factor receptor monoclonal antibodies, more clinical trials with larger sample size are needed. Through current available data from clinical studies, it can be concluded that the best treatment outcome is achieved by a combination of anti epidermal growth factor receptor monoclonal antibodies with conventional chemotherapy.

Cites

No record.

References

Cite

APA: Copy

YAZDI, MOHAMMAD HOSSEIN, FARAMARZI, MOHAMMAD ALI, NIKFAR, SHEKOUFEH, & ABDOLLAHI, MOHAMMAD. (2015). A COMPREHENSIVE REVIEW OF CLINICAL TRIALS ON EGFR INHIBITORS SUCH AS CETUXIMAB AND PANITUMUMAB AS MONOTHERAPY AND IN COMBINATION FOR TREATMENT OF METASTATIC COLORECTAL CANCER. AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), 7(4 (27)), 134-144. SID. https://sid.ir/paper/313884/en

Vancouver: Copy

YAZDI MOHAMMAD HOSSEIN, FARAMARZI MOHAMMAD ALI, NIKFAR SHEKOUFEH, ABDOLLAHI MOHAMMAD. A COMPREHENSIVE REVIEW OF CLINICAL TRIALS ON EGFR INHIBITORS SUCH AS CETUXIMAB AND PANITUMUMAB AS MONOTHERAPY AND IN COMBINATION FOR TREATMENT OF METASTATIC COLORECTAL CANCER. AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB)[Internet]. 2015;7(4 (27)):134-144. Available from: https://sid.ir/paper/313884/en

IEEE: Copy

MOHAMMAD HOSSEIN YAZDI, MOHAMMAD ALI FARAMARZI, SHEKOUFEH NIKFAR, and MOHAMMAD ABDOLLAHI, “A COMPREHENSIVE REVIEW OF CLINICAL TRIALS ON EGFR INHIBITORS SUCH AS CETUXIMAB AND PANITUMUMAB AS MONOTHERAPY AND IN COMBINATION FOR TREATMENT OF METASTATIC COLORECTAL CANCER,” AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB), vol. 7, no. 4 (27), pp. 134–144, 2015, [Online]. Available: https://sid.ir/paper/313884/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops